Skip to main content
. Author manuscript; available in PMC: 2010 Jul 14.
Published in final edited form as: J Immunol. 2005 Jan 1;174(1):164–173. doi: 10.4049/jimmunol.174.1.164

FIGURE 9.

FIGURE 9

Treg cells in psoriatic epidermis and dermis. A, The percentage of CD25highCTLA-4+ Treg cells in psoriatic epidermis and dermis. Data are the summary of three independent experiments. Results are expressed as the mean ± SEM. B, Psoriatic peripheral blood CD4+CD25− T cells (designated CD25−) were cultured with allogeneic APCs in the presence or the absence of lesional skin dermal CD25+ cells (designated dermal CD25+) at the indicated ratios. Proliferation was assessed by [3H]thy-midine incorporation assay. The relative inhibitory function of psoriatic lesional dermal CD25+ cells is expressed as the percent response of alloantigen-stimulated CD4+CD25− T cells. The proliferation of alloantigen-stimulated CD4+CD25− T cells was normalized to 100%. Data are the summary of three (normal) and three (psoriatic) independent experiments. Results are expressed as the mean ± SEM. C, Comparison of the relative inhibitory function of psoriatic lesional dermal CD25+ T cells and normal peripheral blood CD4+CD25high T cells (as described in Fig. 3, B and D, and Fig. 9B). The relative inhibitory function of psoriatic lesional dermal CD25+ cells and normal peripheral blood CD4+CD25high T cells is expressed as the percent response of alloantigen-stimulated psoriatic and normal CD4+CD25− T cells at the indicated ratios, respectively. The proliferation of alloantigen-stimulated CD4+CD25− T cells was normalized to 100%. Data are the summary of three (normal) and two (psoriatic) independent experiments, each with at least triplicate determinations. Results are expressed as the mean; lines represent best-fit curves (solid, normal; dotted, psoriasis).